Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
Featured Showcases
Photonics West Showcase
Optics+Photonics Showcase
Press Releases
Menu
Press Release

Quantel's Solutis Granted FDA Clearance

Date Announced: 13 Aug 2013

Selective laser trabeculoplasty (SLT) Glaucoma Treatment Introduced to U.S. Market.

CLERMONT-FERRAND, France, Aug. 13, 2013 /PRNewswire/ -- Quantel Medical, a world leader in ophthalmic ultrasound and laser devices, today announced that Solutis™, an SLT (selective laser trabeculoplasty) glaucoma laser, has been approved for clinical use by the U.S. Food and Drug Administration.

This approval by the FDA follows the expiration of a patent issued to Massachusetts General Hospital, which restricted Quantel Medical and several other laser manufacturers from marketing SLT within the United States. Quantel has been providing SLT technology to customers outside the United States since 2007.

SLT is an effective first-line and adjunct therapy option for reducing intraocular pressure (IOP) in glaucoma patients. The non-invasive procedure delivers targeted laser energy, inducing a regenerative response at the cellular level. Due to the laser energy's gentle application, the treatment is repeatable, as well as not associated with the ocular and systemic side effects or compliance issues commonly linked to glaucoma drugs.

In use since 2007, Quantel's Solutis laser offers several clinician-friendly features, facilitating easy integration into a hospital or clinical setting. The design is adaptable to a physician's current slit lamp, eliminating the need for dedicated space and lowering end-user cost.

The compact design also allows for easy transport from room to room or office to office, and includes convenient storage accessories when not in use.

"This FDA market clearance of our SLT laser marks an important step in Quantel's strategy for the U.S. market." said Mr. Jean-Marc Gendre, CEO of Quantel Medical.

"Solutis has proven to be an attractive laser solution worldwide, and we are proud to now offer this laser alongside our robust line of multispot and YAG lasers. Our laser product line is uniquely designed to create combination systems, allowing for multiple laser applications in a single configuration, meeting the specific needs of each ophthalmology practice."

Source: Quantel

Contact

via web site

E-mail: via web site

Web Site: www.quantel-medical.com

© 2024 SPIE Europe
Top of Page